Canagliflozin: first global approval (Q38111292)

29 August 2017

title

Canagliflozin: first global approval (English)

1 reference

29 August 2017

2

Lesley J Scott

1 reference

29 August 2017

Shelley Elkinson

1

1 reference

29 August 2017

publication date

1 June 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

73

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

979-988

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0064-9

29 August 2017

exact match

0 references

cites work

Renal glucose reabsorption inhibitors to treat diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0064-9

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0064-9

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0064-9

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0064-9

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0064-9

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0064-9

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0064-9

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23729000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23729000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23729000

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-013-0064-9

1 reference

Dimensions Publication ID

29 August 2017

1047489277

0 references

1 reference